Renal Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Drug Class (ACE Inhibitors, Angiotensin-II Receptor Blockers, Diuretics, Antihypertensive Drugs, Others); Route of Administration (Oral, Intravenous); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, e-commerce, Others)
Renal medicine, or nephrology, involves the care of patients with all forms of kidney disease. A renal disease can be attributed to a variety of causes which, include genetics, injuries and medicine. Renal diseases are becoming a significant health issue among the general population.
The renal drugs market is driving due to the increasing prevalence and incidence of chronic kidney disease globally. However, the availability of alternative diagnosis and treatments such as dialysis, and kidney transplant might also impede the market growth of the global renal drugs market. .
The "Renal Drugs Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of renal drugs market with detailed market segmentation by drug class, route of administration and distribution channel. The renal drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in renal drugs market and offers key trends and opportunities in the market.
The renal drugs market is segmented on the basis of drug class, route of administration and distribution channel. On the basis of drug class, the market is categorized as ACE inhibitors, angiotensin-II receptor blockers, diuretics, antihypertensive drugs and others. Based on route of administration, the market is categorized oral and intravenous. On the basis of distribution channel, the market is categorized hospital pharmacy, retail pharmacy and E-commerce and others.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the renal drugs market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The renal drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting renal drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the renal drugs market in these regions.
Get more information on this report :
The report covers key developments in the renal drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from renal drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for renal drugs in the global market. Below mentioned is the list of few companies engaged in the renal drugs market.
The report also includes the profiles of key players in renal drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Cardinal Health, Inc.
Fresenius SE & Co. KgaA
Dava Pharmaceuticals Inc
F. Hoffmann-La Roche AG,
Endo International plc
Bausch Health Companies Inc.
Teva Pharmaceuticals Industries Ltd
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Get more information on this report :
The List of Companies
1. Apotex Inc.
2. Cardinal Health, Inc.
3. Fresenius SE & Co. KgaA
4. Dava Pharmaceuticals Inc
5. Mylan N.V.
6. F. Hoffmann-La Roche AG,
7. Endo International plc
8. Bausch Health Companies Inc.
10. Teva Pharmaceuticals Industries Ltd